...
首页> 外文期刊>Applied and Environmental Microbiology >Deoxysugar Transfer during Chromomycin A3 Biosynthesis in Streptomyces griseus subsp. griseus: New Derivatives with Antitumor Activity
【24h】

Deoxysugar Transfer during Chromomycin A3 Biosynthesis in Streptomyces griseus subsp. griseus: New Derivatives with Antitumor Activity

机译:在灰色链霉菌亚种中嗜铬霉素A3生物合成过程中的脱氧糖转移。 griseus:具有抗肿瘤活性的新衍生物

获取原文
           

摘要

Chromomycin A3 is an antitumor drug produced by Streptomyces griseus subsp. griseus. It consists of a tricyclic aglycone with two aliphatic side chains and two O-glycosidically linked saccharide chains, a disaccharide of 4-O-acetyl-d-oliose (sugar A) and 4-O-methyl-d-oliose (sugar B), and a trisaccharide of d-olivose (sugar C), d-olivose (sugar D), and 4-O-acetyl-l-chromose B (sugar E). The chromomycin gene cluster contains four glycosyltransferase genes (cmmGI, cmmGII, cmmGIII, and cmmGIV), which were independently inactivated through gene replacement, generating mutants C60GI, C10GII, C10GIII, and C10GIV. Mutants C10GIV and C10GIII produced the known compounds premithramycinone and premithramycin A1, respectively, indicating the involvement of CmmGIV and CmmGIII in the sequential transfer of sugars C and D and possibly also of sugar E of the trisaccharide chain, to the 12a position of the tetracyclic intermediate premithramycinone. Mutant C10GII produced two new tetracyclic compounds lacking the disaccharide chain at the 8 position, named prechromomycin A3 and prechromomycin A2. All three compounds accumulated by mutant C60GI were tricyclic and lacked sugar B of the disaccharide chain, and they were named prechromomycin A4, 4A-O-deacetyl-3A-O-acetyl-prechromomycin A4, and 3A-O-acetyl-prechromomycin A4. CmmGII and CmmGI are therefore responsible for the formation of the disaccharide chain by incorporating, in a sequential manner, two d-oliosyl residues to the 8 position of the biosynthetic intermediate prechromomycin A3. A biosynthetic pathway is proposed for the glycosylation events in chromomycin A3 biosynthesis.
机译:嗜铬霉素A3是由灰链霉菌亚种产生的抗肿瘤药物。 griseus。它由具有两个脂族侧链和两个O-糖苷连接的糖链的三环糖苷配基,4-O-乙酰基-d-寡糖(糖A)和4-O-甲基-d-寡糖(糖B)的二糖组成。 ,以及d-寡糖(糖C),d-寡糖(糖D)和4-O-乙酰基-1-铬B(糖E)的三糖。染色体霉素基因簇包含四个糖基转移酶基因(cmmGI,cmmGII,cmmGIII和cmmGIV),它们通过基因替换而独立失活,从而产生突变体C60GI,C10GII,C10GIII和C10GIV。突变体C10GIV和C10GIII分别产生了已知的化合物普米曲霉素和普米霉素A1,表明CmmGIV和CmmGIII参与了三糖链的糖C和D以及可能的糖E顺序转移至四环中间体的12a位普雷西霉素。突变体C10GII产生了两个在8位缺少二糖链的新四环化合物,分别称为前染色体霉素A3和前染色体霉素A2。突变体C60GI积累的所有三种化合物均为三环且缺乏双糖链的糖B,它们分别被称为前铬霉素A4、4A-O-脱乙酰基-3A-O-乙酰基-前铬霉素A4和3A-O-乙酰基-前铬霉素A4。因此,CmmGII和CmmGI负责通过将两个d-寡糖残基依次引入生物合成中间体前生霉素A3的8位来形成二糖链。提出了一种生物合成途径用于嗜铬菌素A3生物合成中的糖基化事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号